Skip to main content
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Ndukwe, Henry C. and Nishtala, Prasad S. 2016. Temporal trends for donepezil utilization among older people. International Clinical Psychopharmacology, Vol. 31, Issue. 3, p. 170.

    Zilkens, Renate R. Duke, Janine Horner, Barbara Semmens, James B. and Bruce, David G. 2014. Australian population trends and disparities in cholinesterase inhibitor use, 2003 to 2010. Alzheimer's & Dementia, Vol. 10, Issue. 3, p. 310.

    Cherubini, Antonio Corsonello, Andrea and Lattanzio, Fabrizia 2012. Underprescription of Beneficial Medicines in Older People. Drugs & Aging, Vol. 29, Issue. 6, p. 463.


Prescribing trends in cognition enhancing drugs in Australia

  • Samantha A. Hollingworth (a1) and Gerard J. Byrne (a2)
  • DOI:
  • Published online: 30 July 2010

Background: This study sought to examine the trends in the prescribing of subsidized and unsubsidized cognition enhancing drugs (CEDs) in Australia over five years from 2002 to 2007. Subsidized cholinesterase inhibitor medication could be prescribed to people with mild to moderate Alzheimer's disease (AD) once a specialist physician had confirmed this diagnosis. Memantine was available for use in moderately severe AD but not subsidized.

Methods: We analyzed the Medicare Australia and Drug Utilisation Sub-Committee databases for CED prescription data, 2002–2007, by gender, age and prescriber class. Aggregated prescription data for each medication were converted to defined daily doses (DDD) per 1000 persons per day using national census data.

Results: There were 1,583,667 CED prescriptions dispensed during the study period. CED use increased 58% from 0.91 to 1.56 DDD/1000 persons/day between 2002 and 2007. Peak use was in those aged 85–89 years. Age-adjusted utilization was slightly higher in females than males. Donepezil was the most widely used CED (66%), followed by galantamine (27%) then memantine (4%). General practitioners prescribed the majority of CEDs. Geriatricians exhibited a greater preference for galantamine than other prescribers. CED dispensing peaked towards the end of each calendar year, reflecting stockpiling by patients under the influence of a federal safety net subsidy.

Conclusions: Despite subsidized access to CEDs in Australia, only a minority of people with AD was prescribed these drugs during the period of the study. It is likely that the combination of complex prescribing rules and negative perceptions about efficacy or cost-effectiveness might have contributed to these findings.

Corresponding author
Correspondence should be addressed to: Dr Samantha A Hollingworth, The University of Queensland, School of Population Health, Herston Road, Herston QLD 4006, Australia. Phone: +61 71 3365 5516; Fax: +61 7 3365 5442. Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

R. T. Bartus , R. L., III Dean , B. Beer and A. S. Lippa (1982). The cholinergic hypothesis of geriatric memory dysfunction. Science, 217, 408414.

H. Brodaty and M. Gresham (1989). Effect of a training programme to reduce stress in carers of patients with dementia. BMJ, 299, 13751379.

H. Brodaty , P. Sachdev and T. M. Anderson (2005). Dementia: new projections and time for an updated response. Australian and New Zealand Journal of Psychiatry, 39, 955958.

N. Herrmann (2007). A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society, 55, 15171523.

R. J. Howard (2007). Donepezil for the treatment of agitation in Alzheimer's disease. New England Journal of Medicine, 357, 13821392.

A. F. Jorm , K. B. Dear and N. M. Burgess (2005). Projections of future numbers of dementia cases in Australia with and without prevention. Australian and New Zealand Journal of Psychiatry, 39, 959963.

E. Loveman (2006). The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technology Assessment, 10, iii–iv, ix–xi, 1160.

C. G. Lyketsos , M. Steinberg , J. T. Tschanz , M. C. Norton , D. C. Steffens and J. C. Breitner (2000). Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. American Journal of Psychiatry, 157, 708714.

M. Mamdani , M. Rapoport , K. I. Shulman , N. Herrmann and P. A. Rochon (2005). Mental health-related drug utilization among older adults: prevalence, trends, and costs. American Journal of Geriatric Psychiatry, 13, 892900.

R. C. Oude Voshaar , A. Burns and M. G. Olde Rikkert (2006). Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs. International Journal of Geriatric Psychiatry, 21, 2931.

A. Pariente , C. Helmer , Y. Merliere , N. Moore , A. Fourrier-Reglat and J. F. Dartigues (2008). Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiology and Drug Safety, 17, 655660.

L. Y. Park-Wyllie , M. M. Mamdani , P. Li , S. S. Gill , A. Laupacis and D. N. Juurlink (2009). Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. Public Library of Science (PLoS) Medicine, 6, e1000157.

M. Robinson , D. Rowett , A. Leverton and V. Mabbott (2009). Changes in utilisation of anticholinergic drugs after initiation of cholinesterase inhibitors. Pharmacoepidemiology and Drug Safety, 18, 659664.

K. Smith (2008). High prevalence of dementia and cognitive impairment in indigenous Australians. Neurology, 71, 14701473.

A. Takeda (2006). A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease. International Journal of Geriatric Psychiatry, 21, 1728.

G. K. Wilcock , C. G. Ballard , J. A. Cooper and H. Loft (2008). Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry, 69, 341348.

B. Winblad , R. W. Jones , Y. Wirth , A. Stoffler and H. J. Mobius (2007). Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomized clinical trials. Dementia and Geriatric Cognitive Disorders, 24, 2027.

World Health Organization (2008). ATC/DDD Index. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Available at

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Psychogeriatrics
  • ISSN: 1041-6102
  • EISSN: 1741-203X
  • URL: /core/journals/international-psychogeriatrics
Please enter your name
Please enter a valid email address
Who would you like to send this to? *